Table 2 Adherence and change in laboratory parameters after HU treatment

From: Hydroxyurea mobile directly observed therapy versus standard monitoring in patients with sickle cell anemia: a phase 2 randomized trial

Parameter

HU m-DOT (Mdn (IQR))

n = 36

Standard (Mdn (IQR))

n = 39

P-value

Adherence (MPR)

1.00 (0.98−1.04)

0.99 (0.98−1.00)

0.147

Reticulocyte count

−3.83 (−7.91, −1.51)

−3.38 (−7.79, −1.20)

0.994

LDH (u/L)

−174.00 (−327.00, −27.00)

−79.00 (−221.25, −8.75)

0.137

WBC (Cells/µL)

−2.92 (−4.57, −1.49)

−3.37 (−4.68, −0.89)

0.863

Neutrophil (Cells/µL)

−1.44 (−3.15, −0.11)

−2.21 (−3.36, −0.68)

0.252

Hb (g/dL)

0.45 (−0.10, 0.90)

0.40 (0.10, 0.80)

0.778

HbF (%)

2.80 (1.30, 4.80)

2.30 (1.40, 6.30)

0.564

MCV (fL)

8.95 (3.78, 13.85)

8.70 (4.60, 14.60)

0.965

  1. HU hydroxyurea, m-DOT mobile directly observed therapy, Mdn median, IQR interquartile range, Standard standard monitoring, MPR medication possession ratio, Hb total hemoglobin, LDH lactate dehydrogenase, WBC white blood cell count, HbF fetal hemoglobin, MCV mean corpuscular volume.
Back to article page